Humanwell Healthcare's (SHA:600079) unit, Humanwell PuraCap Pharmaceuticals (Wuhan), received a drug registration certificate from China's National Medical Products Administration for its vinorelbine tartrate soft capsules, according to a Shanghai bourse filing on Saturday.
The Chinese pharmaceutical company's shares rose 1% during Monday's afternoon trade.
The drug is used as a treatment for unresectable locally advanced or metastatic non-small cell lung cancer and metastatic breast cancer, either as monotherapy or in combination chemotherapy.